Encainide (BioDeep_00000006391)
Secondary id: BioDeep_00001868244
human metabolite blood metabolite Chemicals and Drugs
代谢物信息卡片
(+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide
化学式: C22H28N2O2 (352.2150668)
中文名称: (±)-4-甲氧基-N-[2-[2-(1-甲基-2-哌啶基)乙基]苯基]苯甲酰胺, 恩卡尼
谱图信息:
最多检出来源 Mus musculus(blood) 45.45%
分子结构信息
SMILES: CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC
InChI: InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)
描述信息
All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.
C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BC - Antiarrhythmics, class ic
D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
D049990 - Membrane Transport Modulators
C93038 - Cation Channel Blocker
同义名列表
16 个代谢物同义名
(+-)-4-Methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide; 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide; BENZAMIDE, 4-METHOXY-N-[2-[2-(1-METHYL-2-PIPERIDINYL)ETHYL]PHENYL]-; 4-methoxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide; 4-Methoxy-2-[2-(1-methyl-2-piperidyl)ethyl]benzanilide; Bristol-myers squibb brand OF encainide hydrochloride; Bristol myers squibb brand OF encainide hydrochloride; (+-)-2-[2-(1-Methyl-2-piperidyl)ethyl]-p-anisanilide; Encainide hydrochloride, (+-)-isomer; Encainide hydrochloride; Encainide, (-)-isomer; Encainide, (+)-isomer; Encainidum; Encainide; Encainida; Enkaid
数据库引用编号
16 个数据库交叉引用编号
- ChEBI: CHEBI:4788
- KEGG: C06978
- KEGGdrug: D07894
- PubChem: 48041
- HMDB: HMDB0015359
- Metlin: METLIN66566
- DrugBank: DB01228
- ChEMBL: CHEMBL315838
- Wikipedia: Encainide
- MeSH: Encainide
- chemspider: 43697
- CAS: 37612-13-8
- CAS: 66778-36-7
- PMhub: MS000019425
- PubChem: 9192
- NIKKAJI: J244.570K
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Cho-Ming Loi, Dennis A Smith, Deepak Dalvie. Which metabolites circulate?.
Drug metabolism and disposition: the biological fate of chemicals.
2013 May; 41(5):933-51. doi:
10.1124/dmd.112.050278. [PMID: 23454828] - Offie P Soldin, Sarah H Chung, Donald R Mattison. Sex differences in drug disposition.
Journal of biomedicine & biotechnology.
2011; 2011(?):187103. doi:
10.1155/2011/187103. [PMID: 21403873] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Kathleen D Liu, Michael A Matthay. Protein C as a surrogate end-point for clinical trials of sepsis.
Critical care (London, England).
2008; 12(2):139. doi:
10.1186/cc6859. [PMID: 18492215] - Boni Elewski, Amir Tavakkol. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.
Therapeutics and clinical risk management.
2005 Dec; 1(4):299-306. doi:
. [PMID: 18360572] - J L C M Dorne, K Walton, W Slob, A G Renwick. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
2002 Nov; 40(11):1633-56. doi:
10.1016/s0278-6915(02)00117-5. [PMID: 12176090] - Reza Mehvar, Dion R Brocks, Majid Vakily. Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.
Clinical pharmacokinetics.
2002; 41(8):533-58. doi:
10.2165/00003088-200241080-00001. [PMID: 12102640] - W Jung, R Mletzko, M Manz, J Nitsch, B Lüderitz. Efficacy and safety of combination therapy with amiodarone and type I agents for treatment of inducible ventricular tachycardia.
Pacing and clinical electrophysiology : PACE.
1993 Apr; 16(4 Pt 1):778-88. doi:
10.1111/j.1540-8159.1993.tb01658.x. [PMID: 7683805] - C Funck-Brentano, G Thomas, E Jacqz-Aigrain, J M Poirier, T Simon, G Béréziat, P Jaillon. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
The Journal of pharmacology and experimental therapeutics.
1992 Nov; 263(2):780-6. doi:
. [PMID: 1432700] - J Turgeon, T A Wisialowski, W Wong, W A Altemeier, J P Wikswo, D M Roden. Suppression of longitudinal versus transverse conduction by sodium channel block. Effects of sodium bolus.
Circulation.
1992 Jun; 85(6):2221-6. doi:
10.1161/01.cir.85.6.2221. [PMID: 1317273] - H Fronc, R S Porter, C C Nydegger, S E Hessen, S P Kutalek. Encainide dosing in patients with severe renal dysfunction: report of a case and literature review.
Clinical cardiology.
1992 Jan; 15(1):53-7. doi:
10.1002/clc.4960150114. [PMID: 1541077] - J S Fleming, J O Buchanan, F D Yocca, L G Iben, M J Antonaccio. Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis.
Cardiovascular drugs and therapy.
1991 Aug; 5(4):763-8. doi:
10.1007/bf03029752. [PMID: 1909560] - F A Fish, P C Gillette, D W Benson. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
Journal of the American College of Cardiology.
1991 Aug; 18(2):356-65. doi:
10.1016/0735-1097(91)90586-x. [PMID: 1906902] - G Wensing, H Mönig, E E Ohnhaus, H P Hoensch. Pharmacokinetics of encainide in patients with cirrhosis.
Cardiovascular drugs and therapy.
1991 Aug; 5(4):733-9. doi:
10.1007/bf03029748. [PMID: 1909559] - M B Halvorsen, J T Whitmer, C E Halstenson. Hemodialysis clearance of encainide and metabolites.
Therapeutic drug monitoring.
1991 Jul; 13(4):375-8. doi:
10.1097/00007691-199107000-00016. [PMID: 1780973] - J Turgeon, C Funck-Brentano, H T Gray, H N Pavlou, C Prakash, I A Blair, D M Roden. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers.
Clinical pharmacology and therapeutics.
1991 May; 49(5):488-96. doi:
10.1038/clpt.1991.59. [PMID: 1903098] - J M Poirier, M Lebot, G Cheymol. Analysis of encainide and its three major metabolites in plasma by column liquid chromatography.
Journal of chromatography.
1990 Dec; 534(?):223-7. doi:
10.1016/s0378-4347(00)82166-0. [PMID: 2128839] - J Turgeon, H N Pavlou, W Wong, C Funck-Brentano, D M Roden. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias.
The Journal of pharmacology and experimental therapeutics.
1990 Nov; 255(2):642-9. doi:
NULL. [PMID: 2123007] - P Jaillon. Pharmacokinetics and metabolism of encainide.
Cardiovascular drugs and therapy.
1990 Jun; 4 Suppl 3(?):561-5. doi:
10.1007/bf00357031. [PMID: 2125833] - A Dasgupta, I B Rosenzweig, J Turgeon, V A Raisys. Encainide and metabolites analysis in serum or plasma using a reversed-phase high-performance liquid chromatographic technique.
Journal of chromatography.
1990 Mar; 526(1):260-5. doi:
10.1016/s0378-4347(00)82508-6. [PMID: 2111331] - S S Gottlieb, M L Kukin, N Medina, M Yushak, M Packer. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure.
Circulation.
1990 Mar; 81(3):860-4. doi:
10.1161/01.cir.81.3.860. [PMID: 2106401] - B Halawa. [Interactions of quinidine and propranolol with mexiletine, encainide, flecainide and tocainide].
Polski tygodnik lekarski (Warsaw, Poland : 1960).
1990 Mar; 45(10-11):222-4. doi:
. [PMID: 2120685] - A Tartini, M Kesselbrenner. Encainide-induced encephalopathy in a patient with chronic renal failure.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
1990 Feb; 15(2):178-9. doi:
10.1016/s0272-6386(12)80517-8. [PMID: 2105639] - H K Jajoo, R F Mayol, J A LaBudde, I A Blair. Structural characterization of urinary metabolites of the antiarrhythmic drug encainide in human subjects.
Drug metabolism and disposition: the biological fate of chemicals.
1990 Jan; 18(1):28-35. doi:
. [PMID: 1970774] - D J Kazierad, R L Lalonde, T J Hoon, D M Mirvis, M B Bottorff. The effect of diltiazem on the disposition of encainide and its active metabolites.
Clinical pharmacology and therapeutics.
1989 Dec; 46(6):668-73. doi:
10.1038/clpt.1989.203. [PMID: 2513160] - D M Roden, J T Lee, R L Woosley, D S Echt. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
Circulation.
1989 Nov; 80(5):1247-58. doi:
10.1161/01.cir.80.5.1247. [PMID: 2805262] - M Chimienti, M Li Bergolis, M Moizi, J A Salerno. Electrophysiologic and clinical effects of oral encainide in paroxysmal atrioventricular node reentrant tachycardia.
Journal of the American College of Cardiology.
1989 Oct; 14(4):992-8. doi:
10.1016/0735-1097(89)90478-6. [PMID: 2507613] - A K Bajaj, R L Woosley, D M Roden. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide.
Circulation.
1989 Oct; 80(4):994-1002. doi:
10.1161/01.cir.80.4.994. [PMID: 2551538] - J Turgeon, D M Roden. Pharmacokinetic profile of encainide.
Clinical pharmacology and therapeutics.
1989 Jun; 45(6):692-4. doi:
10.1038/clpt.1989.91. [PMID: 2499439] - J Turgeon, C Funck-Brentano, H T Gray, D M Roden. Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids.
Journal of chromatography.
1989 May; 490(1):165-74. doi:
10.1016/s0378-4347(00)82771-1. [PMID: 2503530] - S S Gottlieb, M L Kukin, M Yushak, N Medina, M Packer. Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure.
Annals of internal medicine.
1989 Apr; 110(7):505-9. doi:
10.7326/0003-4819-110-7-505. [PMID: 2493762] - K Selinger, J C Crawhall. Determination of encainide and its metabolites by high-performance liquid chromatography.
Journal of pharmaceutical and biomedical analysis.
1989; 7(3):355-9. doi:
10.1016/0731-7085(89)80102-5. [PMID: 2518704] - D J Kazierad, T J Hoon, M B Bottorff. A high-performance liquid chromatographic method for the determination of encainide and its major metabolites in urine and serum using solid-phase extraction.
Therapeutic drug monitoring.
1989; 11(3):327-31. doi:
10.1097/00007691-198905000-00016. [PMID: 2499083] - W Davies, M Jazayeri, P Tchou. Marked Q-T prolongation due to encainide therapy.
Cardiovascular drugs and therapy.
1988 Sep; 2(3):283-6. doi:
10.1007/bf00054634. [PMID: 3155328] - E Weinhouse, J Tribble, M Jarenwattananon, D B Nudel. Reevaluation of digoxin-encainide interactions using an animal model.
Clinical cardiology.
1988 Jul; 11(7):474-80. doi:
10.1002/clc.4960110708. [PMID: 3138054] - D M Roden, R L Woosley. Clinical pharmacokinetics of encainide.
Clinical pharmacokinetics.
1988 Mar; 14(3):141-7. doi:
10.2165/00003088-198814030-00002. [PMID: 3131058] - J T Barbey, K A Thompson, D S Echt, R L Woosley, D M Roden. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
Circulation.
1988 Feb; 77(2):380-91. doi:
10.1161/01.cir.77.2.380. [PMID: 3123092] - D M Salerno, J Fifield, J Krejci, M Hodges. Encainide-induced hyperglycemia.
The American journal of medicine.
1988 Jan; 84(1):39-44. doi:
10.1016/0002-9343(88)90006-x. [PMID: 3122563] - M J Bartek, R F Mayol, M P Boarman, R E Gammans, D G Gallo. Analysis of encainide and metabolites in plasma and urine by high-performance liquid chromatography.
Therapeutic drug monitoring.
1988; 10(4):446-52. doi:
10.1097/00007691-198804000-00012. [PMID: 3144068] - R N Brogden, P A Todd. Encainide. A review of its pharmacological properties and therapeutic efficacy.
Drugs.
1987 Nov; 34(5):519-38. doi:
10.2165/00003495-198734050-00002. [PMID: 3121275] - S L Chase, G E Sloskey. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
Clinical pharmacy.
1987 Nov; 6(11):839-50. doi:
NULL. [PMID: 3119276] - P Dorian, J M Davy, R E Kates. Pharmacodynamic modeling of antiarrhythmic drug effects--application to 3-methoxy-O-demethyl encainide.
Journal of cardiovascular pharmacology.
1986 Nov; 8(6):1217-22. doi:
10.1097/00005344-198611000-00018. [PMID: 2434749] - D C Harrison, R E Kates, B D Quart. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.
The American journal of cardiology.
1986 Aug; 58(5):66C-73C. doi:
10.1016/0002-9149(86)90107-4. [PMID: 3092622] - B D Quart, D G Gallo, M H Sami, A J Wood. Drug interaction studies and encainide use in renal and hepatic impairment.
The American journal of cardiology.
1986 Aug; 58(5):104C-113C. doi:
10.1016/0002-9149(86)90112-8. [PMID: 2875643] - A W Gomoll, J E Byrne, M J Antonaccio. Electrophysiology, hemodynamic and arrhythmia efficacy model studies on encainide.
The American journal of cardiology.
1986 Aug; 58(5):10C-17C. doi:
10.1016/0002-9149(86)90098-6. [PMID: 3092614] - D M Roden, A J Wood, G R Wilkinson, R L Woosley. Disposition kinetics of encainide and metabolites.
The American journal of cardiology.
1986 Aug; 58(5):4C-9C. doi:
10.1016/0002-9149(86)90097-4. [PMID: 3092618] - R H Bergstrand, T Wang, D M Roden, G R Avant, W W Sutton, L A Siddoway, H Wolfenden, R L Woosley, G R Wilkinson, A J Wood. Encainide disposition in patients with chronic cirrhosis.
Clinical pharmacology and therapeutics.
1986 Aug; 40(2):148-54. doi:
10.1038/clpt.1986.155. [PMID: 3089668] - R H Bergstrand, T Wang, D M Roden, W J Stone, H T Wolfenden, R L Woosley, G R Wilkinson, A J Wood. Encainide disposition in patients with renal failure.
Clinical pharmacology and therapeutics.
1986 Jul; 40(1):64-70. doi:
10.1038/clpt.1986.140. [PMID: 3087679] - A W Gomoll, J E Byrne, R F Mayol. Comparative antiarrhythmic actions of encainide and its major metabolites.
Archives internationales de pharmacodynamie et de therapie.
1986 Jun; 281(2):277-97. doi:
. [PMID: 3092755] - C B McAllister, H T Wolfenden, W S Aslanian, R L Woosley, G R Wilkinson. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations.
Xenobiotica; the fate of foreign compounds in biological systems.
1986 May; 16(5):483-90. doi:
10.3109/00498258609050253. [PMID: 3090789] - J Morganroth, P Pool, R Miller, P H Hsu, I Lee, D M Clark. Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias.
The American journal of cardiology.
1986 Apr; 57(10):769-74. doi:
10.1016/0002-9149(86)90611-9. [PMID: 3083665] - R L Woosley, D M Roden, G H Dai, T Wang, D Altenbern, J Oates, G R Wilkinson. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.
Clinical pharmacology and therapeutics.
1986 Mar; 39(3):282-7. doi:
10.1038/clpt.1986.40. [PMID: 3081292] - R L Woosley, D S Echt, D M Roden. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
The American journal of cardiology.
1986 Jan; 57(3):25B-33B. doi:
10.1016/0002-9149(86)90995-1. [PMID: 3080860] - P Dumoulin, P Jaillon, A Kher, J M Poirier, G Cheymol, J Valty, D Flammang, P Coumel, J L Medvedowsky, C Barnay. [Anti-arrhythmia effect of long-term encainide in chronic ventricular extrasystole].
Archives des maladies du coeur et des vaisseaux.
1985 Oct; 78 Spec No(?):105-9. doi:
NULL. [PMID: 2420299] - P Dumoulin, P Jaillon, A Kher, J M Poirier, G Cheymol, J Valty, D Flammang, P Coumel, J L Medvedowsky, C Barnay. Long-term efficacy and safety of oral encainide in the treatment of chronic ventricular ectopic activity: relationship to plasma concentrations--a French multicenter trial.
American heart journal.
1985 Sep; 110(3):575-81. doi:
10.1016/0002-8703(85)90077-8. [PMID: 2412428] - J Thale, H Klein, R G Shanks, F Bender. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
Zeitschrift fur Kardiologie.
1985 Apr; 74(4):220-7. doi:
. [PMID: 2408392] - M F Arnsdorf, G A Schmidt, G J Sawicki. Effects of encainide on the determinants of cardiac excitability in sheep Purkinje fibers.
The Journal of pharmacology and experimental therapeutics.
1985 Jan; 232(1):40-8. doi:
NULL. [PMID: 3917508] - G P Sanna. New drugs in the management of ventricular arrhythmias.
Giornale italiano di cardiologia.
1984 Oct; 14(10):788-97. doi:
. [PMID: 6083894] - A K Dawson, D M Roden, H J Duff, R L Woosley, R F Smith. Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog.
The American journal of cardiology.
1984 Sep; 54(6):654-8. doi:
10.1016/0002-9149(84)90267-4. [PMID: 6475789] - D G McDevitt. The clinical pharmacology of lidocaine congeners--review of encainide, flecainide, lorcainide and tocainide.
European heart journal.
1984 Sep; 5 Suppl B(?):63-6. doi:
10.1093/eurheartj/5.suppl_b.63. [PMID: 6437818] - A M Gillis, R E Kates. Clinical pharmacokinetics of the newer antiarrhythmic agents.
Clinical pharmacokinetics.
1984 Sep; 9(5):375-403. doi:
10.2165/00003088-198409050-00001. [PMID: 6437721] - R Latini, A M Gillis, R E Kates. Myocardial uptake of encainide and its two major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, in the dog.
Journal of cardiovascular pharmacology.
1984 Jul; 6(4):663-7. doi:
10.1097/00005344-198407000-00017. [PMID: 6206322] - D M Roden, A K Dawson, H J Duff, R L Woosley, R F Smith. Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia.
Journal of cardiovascular pharmacology.
1984 Jul; 6(4):588-95. doi:
10.1097/00005344-198407000-00006. [PMID: 6206311] - T Wang, D M Roden, H T Wolfenden, R L Woosley, A J Wood, G R Wilkinson. Influence of genetic polymorphism on the metabolism and disposition of encainide in man.
The Journal of pharmacology and experimental therapeutics.
1984 Mar; 228(3):605-11. doi:
NULL. [PMID: 6423808] - E L Carey, H J Duff, D M Roden, R K Primm, G R Wilkinson, T Wang, J A Oates, R L Woosley. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.
The Journal of clinical investigation.
1984 Feb; 73(2):539-47. doi:
10.1172/jci111241. [PMID: 6421879] - R E Kates. Metabolites of cardiac antiarrhythmic drugs: their clinical role.
Annals of the New York Academy of Sciences.
1984; 432(?):75-89. doi:
10.1111/j.1749-6632.1984.tb14510.x. [PMID: 6441496] - R L Woosley, D M Roden. Importance of metabolites in antiarrhythmic therapy.
The American journal of cardiology.
1983 Sep; 52(6):3C-7C. doi:
10.1016/0002-9149(83)90625-2. [PMID: 6194679] - H J Duff, A K Dawson, D M Roden, J A Oates, R F Smith, R L Woosley. Electrophysiologic actions of O-demethyl encainide: an active metabolite.
Circulation.
1983 Aug; 68(2):385-91. doi:
10.1161/01.cir.68.2.385. [PMID: 6861313] - R A Winkle, F Peters, R E Kates, D C Harrison. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide.
The American journal of cardiology.
1983 Apr; 51(7):1182-8. doi:
10.1016/0002-9149(83)90366-1. [PMID: 6404150] - F Follath, U Ganzinger, E Schuetz. Reliability of antiarrhythmic drug plasma concentration monitoring.
Clinical pharmacokinetics.
1983 Jan; 8(1):63-82. doi:
10.2165/00003088-198308010-00004. [PMID: 6404580] - D L Ross, D Y Sze, D L Keefe, C D Swerdlow, D S Echt, J C Griffin, R A Winkle, J W Mason. Antiarrhythmic drug combinations in the treatment of ventricular tachycardia.
Circulation.
1982 Dec; 66(6):1205-10. doi:
10.1161/01.cir.66.6.1205. [PMID: 6814784] - J L Anderson, J R Stewart, T A Johnson, J R Lutz, B Pitt. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
Journal of cardiovascular pharmacology.
1982 Sep; 4(5):812-9. doi:
10.1097/00005344-198209000-00018. [PMID: 6182414] - C R Tucker, R A Winkle, F A Peters, D C Harrison. Acute hemodynamic effects of intravenous encainide in patients with heart disease.
American heart journal.
1982 Aug; 104(2 Pt 1):209-15. doi:
10.1016/0002-8703(82)90194-6. [PMID: 6808816] - D M Roden, H J Duff, D Altenbern, R L Woosley. Antiarrhythmic activity of the O-demethyl metabolite of encainide.
The Journal of pharmacology and experimental therapeutics.
1982 Jun; 221(3):552-7. doi:
. [PMID: 6806461] - R E Kates, D C Harrison, R A Winkle. Metabolite cumulation during long-term oral encainide administration.
Clinical pharmacology and therapeutics.
1982 Apr; 31(4):427-32. doi:
10.1038/clpt.1982.55. [PMID: 6800679] - W M Jackman, D P Zipes, G V Naccarelli, R L Rinkenberger, J J Heger, E N Prystowsky. Electrophysiology of oral encainide.
The American journal of cardiology.
1982 Apr; 49(5):1270-8. doi:
10.1016/0002-9149(82)90055-8. [PMID: 6801954] - R G Samuelsson, D C Harrison. Electrophysiologic evaluation of encainide with use of monophasic action potential recording.
The American journal of cardiology.
1981 Nov; 48(5):871-6. doi:
10.1016/0002-9149(81)90352-0. [PMID: 6795911] - R A Winkle, F Peters, R E Kates, C Tucker, D C Harrison. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias.
Circulation.
1981 Aug; 64(2):290-6. doi:
10.1161/01.cir.64.2.290. [PMID: 6788400] - J H Ro, J Gillon, J Kupersmith. Electrophysiologic effects of encainide following acute coronary occlusion in dogs.
Journal of cardiovascular pharmacology.
1981 May; 3(3):532-40. doi:
10.1097/00005344-198105000-00012. [PMID: 6168834] - P Jaillon, S de la Rosa, J C Griffin, R A Winkle, D C Harrison. Effects of encainide (MJ9067) on the ventricular fibrillation threshold in anesthetized dogs.
Journal of cardiovascular pharmacology.
1980 Sep; 2(5):517-26. doi:
10.1097/00005344-198009000-00003. [PMID: 6157946] - D M Roden, S B Reele, S B Higgins, R F Mayol, R E Gammans, J A Oates, R L Woosley. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
The New England journal of medicine.
1980 Apr; 302(16):877-82. doi:
10.1056/nejm198004173021601. [PMID: 6767186] - K M Lovette, H Y Chuang, A F Mohammad, R G Mason. The subcellular distribution and partial characterization of cholinesterase activities of canine platelets.
Biochimica et biophysica acta.
1976 Apr; 428(2):355-68. doi:
10.1016/0304-4165(76)90043-x. [PMID: 6047]